Enhanced Interleukin-1 Activity Contributes to Exercise Intolerance in Patients with Systolic Heart Failure
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Heart failure (HF) is a complex clinical syndrome characterized by impaired cardiac function and poor exercise tolerance. Enhanced inflammation is associated with worsening outcomes in HF patients and may play a direct role in disease progression. Interleukin-1β (IL-1β) is a pro-inflammatory cytokine that becomes chronically elevated in HF and exerts putative negative inotropic effects. METHODS AND RESULTS: We developed a model of IL-1β-induced left ventricular (LV) dysfunction in healthy mice that exhibited a 32% reduction in LV fractional shortening (P<0.001) and a 76% reduction in isoproterenol response (P<0.01) at 4 hours following a single dose of IL-1β 3 mcg/kg. This phenotype was reproducible in mice injected with plasma from HF patients and fully preventable by pretreatment with IL-1 receptor antagonist (anakinra). This led to the design and conduct of a pilot clinical to test the effect of anakinra on cardiopulmonary exercise performance in patients with HF and evidence of elevated inflammatory signaling (n = 7). The median peak oxygen consumption (VO(2)) improved from 12.3 [10.0, 15.2] to 15.1 [13.7, 19.3] mL · kg(-1) · min(-1) (P = 0.016 vs. baseline) and median ventilator efficiency (V(E)/VCO(2) slope) improved from 28.1 [22.8, 31.7] to 24.9 [22.9, 28.3] (P = 0.031 vs. baseline). CONCLUSIONS: These findings suggest that IL-1β activity contributes to poor exercise tolerance in patients with systolic HF and identifies IL-1β blockade as a novel strategy for pharmacologic intervention. TRIAL REGISTRATION: ClinicalTrials.gov NCT01300650.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
Heart Disease and Stroke Statistics—2011 Update: A Report From the American Heart Association
Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Adams, R. J., Berry, J. D., Brown, T. M., Carnethon, M. R., Dai, S., de Simone, G., Ford, E. S., et al. (2011) · Circulation · doi:10.1161/cir.0b013e3182009701 · Cited by 6,149
Rehospitalizations among Patients in the Medicare Fee-for-Service Program
Jencks, S. F., Williams, M. V., & Coleman, E. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmsa0803563 · Cited by 5,164
Immunological and inflammatory functions of the interleukin-1 family
Dinarello, C. A. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132612 · Cited by 3,466 · cited 1×
“[5–7] Early investigations in septic cardiomyopathy identified IL-1b as a soluble ‘depressant factor’ in the sera of these patients, producing a concentration-dependent depression of myocyte contractility in vitro [7] Further studies identify a pathologic role for IL-1b in ventricular remodeling, systolic dysfunction,…”
Self-citationBalady, G. J., Arena, R., Sietsema, K., Myers, J., Coke, L., Fletcher, G. F., Forman, D., Franklin, B., Guazzi, M., Gulati, M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181e52e69 · Cited by 1,964
Self-citationThe role of IL-1 in the pathogenesis of heart disease
Bujak, M., & Frangogiannis, N. G. (2009) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-009-0024-y · Cited by 307
Arena, R., Myers, J., & Guazzi, M. (2008) · Heart Failure Reviews · doi:10.1007/s10741-007-9067-5 · Cited by 268 · cited 1×
“[35] Therefore, the improvements in these CPX variables observed in the current investigation may be linked to IL-1b blockade-induced improvements in cardiac function.”
Self-citation
Cited by
Overview of the IL ‐1 family in innate inflammation and acquired immunity
Dinarello, C. A. (2018) · Immunological Reviews · doi:10.1111/imr.12621 · Cited by 1,866
Self-citationTreating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,768
Self-citationInterleukin-18 and IL-18 Binding Protein
Dinarello, C. A., Novick, D., Kim, S., & Kaplanski, G. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00289 · Cited by 938
Self-citationPhysiological and pathological cardiac hypertrophy
Shimizu, I., & Minamino, T. (2016) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2016.06.001 · Cited by 887
Murphy, S. P., Kakkar, R., McCarthy, C. P., & Januzzi, J. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.01.014 · Cited by 738
Interleukin-1 and the Inflammasome as Therapeutic Targets in Cardiovascular Disease
Abbate, A., Toldo, S., Marchetti, C., Kron, J., Van Tassell, B. W., & Dinarello, C. A. (2020) · Circulation Research · doi:10.1161/circresaha.120.315937 · Cited by 730
Self-citationInterleukin-6 Signaling and Anti-Interleukin-6 Therapeutics in Cardiovascular Disease
Ridker, P. M., & Rane, M. (2021) · Circulation Research · doi:10.1161/circresaha.121.319077 · Cited by 691
Innate Immunity and the Failing Heart: The Cytokine Hypothesis Revisited
Mann, D. L. (2015) · Circulation Research · doi:10.1161/circresaha.116.302317 · Cited by 689
The NLRP3 inflammasome in acute myocardial infarction
Toldo, S., & Abbate, A. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.161 · Cited by 665
Self-citationAnti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Everett, B. M., Cornel, J. H., Lainscak, M., Anker, S. D., Abbate, A., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2019) · Circulation · doi:10.1161/circulationaha.118.038010 · Cited by 658
Self-citationTreating inflammation by blocking interleukin-1 in humans
Dinarello, C. A., & van der Meer, J. W. M. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.008 · Cited by 549
Self-citationThe role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Toldo, S., & Abbate, A. (2024) · Nature Reviews Cardiology · doi:10.1038/s41569-023-00946-3 · Cited by 411
Self-citationInflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury
Toldo, S., Mauro, A. G., Cutter, Z., & Abbate, A. (2018) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00158.2018 · Cited by 369
Self-citationAimo, A., Castiglione, V., Borrelli, C., Saccaro, L. F., Franzini, M., Masi, S., Emdin, M., & Giannoni, A. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319870344 · Cited by 343
Immune Cell and Other Noncardiomyocyte Regulation of Cardiac Hypertrophy and Remodeling
Frieler, R. A., & Mortensen, R. M. (2015) · Circulation · doi:10.1161/circulationaha.114.008788 · Cited by 334
Targeting the NLRP3 inflammasome in cardiovascular diseases
Toldo, S., Mezzaroma, E., Buckley, L. F., Potere, N., Di Nisio, M., Biondi-Zoccai, G., Van Tassell, B. W., & Abbate, A. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108053 · Cited by 328
Self-citationTargeting Interleukin-1 in Heart Disease
Van Tassell, B. W., Toldo, S., Mezzaroma, E., & Abbate, A. (2013) · Circulation · doi:10.1161/circulationaha.113.003199 · Cited by 302
Self-citationAbbate, A., Trankle, C. R., Buckley, L. F., Lipinski, M. J., Appleton, D., Kadariya, D., Canada, J. M., Carbone, S., Roberts, C. S., Abouzaki, N., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.014941 · Cited by 300
Self-citationSeropian, I. M., Toldo, S., Van Tassell, B. W., & Abbate, A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.01.014 · Cited by 296
Self-citationAnakinra Therapy for Non-cancer Inflammatory Diseases
Cavalli, G., & Dinarello, C. A. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.01157 · Cited by 292
Self-citationObesity and Heart Failure: Focus on the Obesity Paradox
Carbone, S., Lavie, C. J., & Arena, R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2016.11.001 · Cited by 287
Self-citationVan Tassell, B. W., Arena, R., Biondi-Zoccai, G., McNair Canada, J., Oddi, C., Abouzaki, N. A., Jahangiri, A., Falcao, R. A., Kontos, M. C., Shah, K. B., et al. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.047 · Cited by 281
Self-citationInterleukin-18, more than a Th1 cytokine
Novick, D., Kim, S., Kaplanski, G., & Dinarello, C. A. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.10.014 · Cited by 280
Self-citationRole of Inflammation in Heart Failure
Shirazi, L. F., Bissett, J., Romeo, F., & Mehta, J. L. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0660-3 · Cited by 278
Immune Mechanisms in Heart Failure
Zhang, Y., Bauersachs, J., & Langer, H. F. (2017) · European Journal of Heart Failure · doi:10.1002/ejhf.942 · Cited by 262
Van Tassell, B. W., Canada, J., Carbone, S., Trankle, C., Buckley, L., Oddi Erdle, C., Abouzaki, N. A., Dixon, D., Kadariya, D., Christopher, S., et al. (2017) · Circulation: Heart Failure · doi:10.1161/circheartfailure.117.004373 · Cited by 245
“The adjudicated events included (1) death; (2) cardiac and (3) noncardiac death (in which a direct cause attributable to cardiac disease is not present); (4) hospitalization for HF (in which the primary diagnosis for hospitalization is decompensated HF established as the finding at admission of both of the following c…”
Self-citationAbbate, A., Kontos, M. C., Abouzaki, N. A., Melchior, R. D., Thomas, C., Van Tassell, B. W., Oddi, C., Carbone, S., Trankle, C. R., Roberts, C. S., et al. (2015) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.11.003 · Cited by 160
Self-citationTreating Life-Threatening Myocarditis by Blocking Interleukin-1*
Cavalli, G., Pappalardo, F., Mangieri, A., Dinarello, C. A., Dagna, L., & Tresoldi, M. (2016) · Critical Care Medicine · doi:10.1097/ccm.0000000000001654 · Cited by 96
“Consistently, in patients with refractory heart failure, anakinra treatment was associated with improved exercise tolerance, paralleled by a decrease in blood neutrophils and inflammatory markers CRP, IL-1β, and IL-6 (12).”
BackgroundSelf-citationMyocarditis: An Interleukin-1-Mediated Disease?
De Luca, G., Cavalli, G., Campochiaro, C., Tresoldi, M., & Dagna, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01335 · Cited by 79
“Trend toward decreased CRP levels correlated with the change in LVESVi and LVEDVi AIR-HF (51) (2012) HfrEF and elevated CRP levels (7) Open-label, single-arm, non-randomized design.”
BackgroundResultInfluentialInterleukin-1 Receptor Blockade Rescues Myocarditis-Associated End-Stage Heart Failure
Cavalli, G., Foppoli, M., Cabrini, L., Dinarello, C. A., Tresoldi, M., & Dagna, L. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00131 · Cited by 70
“Consistently, administration of anakinra to patients with refractory heart failure improved exercise tolerance and was associated with a corresponding decrease in major pro-inflammatory mediators CRP, IL-1β, and IL-6 (28).”
BackgroundSelf-citationPulmonary arterial hypertension and the Enigma code of smouldering inflammation
Gomez-Arroyo, J., Abbate, A., & Voelkel, N. F. (2016) · European Respiratory Journal · doi:10.1183/13993003.00996-2016 · Cited by 8
Self-citation
Metadata
- Authors
- Van Tassell, B. W., Arena, R. A., Toldo, S., Mezzaroma, E., Azam, T., Seropian, I. M., Shah, K., Canada, J., Voelkel, N. F., Dinarello, C. A., & Abbate, A.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-16
- Volume
- 7
- Issue
- 3
- Pages
- e33438
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2100934097
- Cited by
- 232
- References
- 7
- FWCI
- 9.21
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.